Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors

Chemical Biology and Drug Design

Volumn 76, Issue 4, 2010, Pages 330-339

  Xiaohe, Zhu ^a   Yu, Qin ^a   Hong, Yan ^a   Xiuqing, Song ^a   Rugang, Zhong ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

antiviral agents; molecular docking; N aryl 2 arylthioacetamides; non nucleoside reverse transcriptase inhibitors; structure activity relationships

Indexed keywords

N (5 CHLORO 2 PYRIDINYL) N' [2 (4 ETHOXY 3 FLUORO 2 PYRIDINYL)ETHYL]THIOUREA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; THIOACETAMIDE DERIVATIVE; UNCLASSIFIED DRUG; VRX 480773;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG BINDING SITE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

BINDING SITES; CELL LINE; COMPUTER SIMULATION; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; THIAZOLES; THIOACETAMIDE; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77956400880     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.01017.x     Document Type: Article

References (34)

1. Mitsuya H., Broder S. (1987) Strategies for antiviral therapy in AIDS. Nature 325 : 773 778.
2. De Clercq E. (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38 : 153 179.
3. Stevens M., De Clercq E., Balzarini J. (2006) The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Chem Rev 26 : 595 625.
4. Meadows D.C., Gervay H.J. (2006) Current developments in HIV chemotherapy. Chem Med Chem 1 : 16 29.
5. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267 : 988 993.
6. Barbaro G., Scozzafava A., Mastrolorenzo A., Supuran C.T. (2005) Highly active antiretroviral therapy: current state of the art new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 11 : 1805 1843.
7. Koup R.A., Merluzzi V.J., Hargrave K.D., Adams J., Grozinger K., Eckner R.J., Sullivan J.L. (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 163 : 966 970.
8. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R. et al. (1995) L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39 : 2602 2605.
9. Freimuth W.W. (1996) Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Bio 394 : 279 289.
10. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van G.J., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., Janssen P.A.J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343 : 470 474. (Pubitemid 120028562)
11. Balzarini J., Pelemans H., Aquaro S., Perno C.F., Witvrouw M., Schols D., De Clercq E., Karlsson A. (1996) Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 50 : 394 401.
12. Goldman M.E., Nunberg J.H., O'Brien J.A., Quintero J.C., Schleif W.A., Freund K.F., Gaul S.L., Saari W.S., Wai J.S., Hoffman J.M., Anderson P.S., Hupe D.J., Emini E.A., Stern A.M. (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 88 : 6863 6867.
13. Patel M., Ko S.S., McHugh R.J.J., Markwalder J.A., Srivastava A.S., Cordova B.C., Klabe R.M., Erickson-Viitanen S., Trainor G.L., Seitz S.P. (1999) Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett 9 : 2805 2810.
14. De Clercq E. (1999) Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 54 : 26 45.
15. Ilina T., Parniak M.A. (2008) Inhibitors of HIV-I reverse transcriptase. Adv Pharmacol 56 : 121 167.
16. Wang Z., Wu B., Kuhen K.L., Bursulaya B., Nguyen T.N., Nguyen D.G., He Y. (2006) Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 16 : 4174 4177.
17. Muraglia E., Kinzel O.D., Laufer R., Miller M.D., Moyer G., Munshi V., Orvieto F., Palumbi M.C., Pescatore G., Rowley M., Williams P.D., Summa V. (2006) Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg Med Chem Lett 16 : 2748 2752.
18. Zhan P., Liu X., Cao Y., Wang Y., Pannecouque C., De Clercq E. (2008) 123-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett 18 : 5368 5371.
19. Zhang Z., Xu W., Koh Y.H., Shim J.H., Girardet J.L., Yeh L.T., Hamatake R.K., Hong Z. (2007) A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 51 : 429 437.
20. Hu R., Barbault F., Delamar M., Zhang R. (2009) Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 17 : 2400 2409.
21. Yong S.R., Ung A.T., Pyne S.G., Skelton B.W., White A.H. (2007) Synthesis of novel 3′-spirocyclic-oxindole derivatives and assessment of their cytostatic activities. Tetrahedron 63 : 5579 5586.
22. Rodinovskaya L.A., Shestopalov A.M., Gromova A.V., Shestopalov A.A. (2008) One-pot synthesis of diverse 4-di(tri)fluoromethyl-3-cyanopyridine-2(1H)- thiones and their utilities in the cascade synthesis of annulated heterocycles. J Comb Chem 10 : 313 322.
23. Liu K., Lu H., Hou L., Qi Z., Teixeira C., Barbault F., Fan B.T., Liu S., Jiang S., Xie L. (2008) Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem 51 : 7843 7854.
24. Kanamoto T., Kashiwada Y., Kanbara K., Gotoh K., Yoshimori M., Goto T., Sano K., Nakashima H. (2001) Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 45 : 1225 1230.
25. Silvestri R., Artico M., De Martino G., Ragno Ri., Massa S., Loddo R., Murgioni C., Loi A.G., La Colla P., Pani A. (2002) Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5- nitroimidazoles targeted at the HIV-1 reverse transcriptase. J Med Chem 45 : 1567 1576.
26. De Martino G., La Regina G., Di Pasquali A., Ragno R., Bergamini A., Ciaprini C., Sinistro A., Maga G., Crespan E., Artico M., Silvestri R. (2005) Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem 48 : 4378 4388.
27. Shrestha A.R., Ali H.I., Ashida N., Nagamatsu T. (2008) Antitumor studies, part 5: synthesis antitumor activity and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins. Bioorg Med Chem 16 : 9161 9170.
28. Kovac A., Konc J., Vehar B., Bostock J.M., Chopra I., Janezic D., Gobec S. (2008) Discovery of new inhibitors of d-Alanine: d-Alanine ligase by structure-based virtual screening. J Med Chem 51 : 7442 7448.
29. Ding J., Das K., Tantillo C., Zhang W., Clark A.D.J., Jessen S., Lu X. et al. (1995) Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2.8 A resolution. Structure 3 : 365 379.
30. Ren J., Diprose J., Warren J., Esnouf R.M., Bird L.E., Ikemizu S., Slater M., Milton J., Balzarini J., Stuart D.I., Stammers D.K. (2000) Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases: structural and biochemical analyses. J Biol Chem 275 : 5633 5639.
31. Schafer W., Friebe W.G., Leinert H., Mertens A., Poll T., von der Saal W., Zilch H., Nuber B., Ziegler M.L. (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. J Med Chem 36 : 726 732.
32. Jonckheere H., Anne J., De Clercq E. (2000) The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev 20 : 129 154.
33. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., Bozzette S.A. (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18 : 1393 1401.
34. Paul M.K., Mukhopadhyay A.K. (2004) Tyrosine kinase-role and significance in cancer. Int J Med Sci 1 : 101 115.